BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Analysts

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been assigned an average recommendation of “Moderate Buy” from the eighteen research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, twelve have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $130.60.

Several research analysts recently weighed in on the stock. The Goldman Sachs Group reissued a “buy” rating on shares of BioNTech in a research note on Wednesday, March 11th. Truist Financial raised shares of BioNTech to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen raised shares of BioNTech from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright reissued a “buy” rating and set a $130.00 price objective on shares of BioNTech in a research note on Monday, April 27th. Finally, Citigroup reduced their price objective on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th.

Insiders Place Their Bets

In related news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the transaction, the chief operating officer owned 399,387 shares of the company’s stock, valued at $44,156,226.72. This trade represents a 11.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BNTX. Dodge & Cox lifted its stake in BioNTech by 315.7% in the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after buying an additional 2,769,654 shares in the last quarter. GSK plc bought a new position in BioNTech in the fourth quarter valued at approximately $84,711,000. BNP Paribas Financial Markets lifted its stake in BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after buying an additional 474,796 shares in the last quarter. Bank of America Corp DE lifted its stake in BioNTech by 344.4% in the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock valued at $56,544,000 after buying an additional 444,332 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new position in BioNTech in the fourth quarter valued at approximately $41,656,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Stock Up 0.3%

Shares of NASDAQ BNTX opened at $93.66 on Wednesday. The firm has a market capitalization of $23.68 billion, a PE ratio of -15.93 and a beta of 1.36. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00. The firm’s 50-day moving average is $95.62 and its 200-day moving average is $100.63.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%.The firm had revenue of $1.06 billion for the quarter. Equities analysts expect that BioNTech will post -4.71 EPS for the current year.

BioNTech declared that its board has authorized a stock repurchase program on Thursday, May 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 4.2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.